**Sir**,

[@bib5] claimed that 25(OH)D concentration is associated with better cancer outcome, and the observed association of functional variants in vitamin D pathway genes with outcome supports a causal link. This deserves a comment.

First, using arbitrary cut-points to derive subgroups for 25(OH)D is not appropriate when there is a continuous distribution of the values with no obvious modal values.

Second, no adjustments for main confounding clinical variables were performed. For smoking it would have been a catch-22: (a) smokers have lower 25(OH)D ([@bib4]); (b) 25(OH)D is associated with higher risk of tobacco-related cancers ([@bib1]). Similarly, alcohol consumption, obesity, overweight, insulin resistance, type 2 diabetes have an impact on vitamin D status ([@bib3]).

Long ago, in 1998, a prospective survey (NHANES III) investigated 25(OH)D levels with mortality, accounting for age, sex, ethnicity, diabetes, current smoking, body mass index, physical activity, supplementation, season and so on ([@bib2]). Personalised medicine is first about phenotyping not genotyping!
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